Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nick Giannoukakis

Showing results (21-30 of 76) with videos related to

Pageof 8
Sort By:
American Journal of Therapeutics|November 11, 2005
Gene therapy for type 1 diabetesNick Giannoukakis, Massimo Trucco
Clinical Immunology (Orlando, Fla.)|July 15, 2015
Nanotherapeutics for autoimmunity becomes mainstreamNick Giannoukakis, Wilson S Meng
Frontiers in Endocrinology|August 2, 2023
Editorial: Diabetes and non-alcoholic fatty liver disease: points of physiological and mechanistic intersection and current co-therapeutic approachesNick Giannoukakis, Kyle S McCommis
Expert Opinion on Drug Delivery|October 21, 2010
Drug delivery technologies for autoimmune diseaseBrett E Phillips, Nick Giannoukakis
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2002
Gene and cell therapies for diabetes mellitus: strategies and clinical potentialNick Giannoukakis, Paul D Robbins
Expert Review of Clinical Immunology|May 19, 2010
Dendritic cell-based therapy in Type 1 diabetes mellitusBrett Phillips, Nick Giannoukakis, Massimo Trucco
Pediatric Diabetes|June 11, 2008
Toward a cure for type 1 diabetes mellitus: diabetes-suppressive dendritic cells and beyondNick Giannoukakis, Brett Phillips, Massimo Trucco
Diabetes|November 21, 2022
Response to Comment on Pietropaolo et al. Incidence of an Insulin-Requiring Hyperglycemic Syndrome in SARS-CoV-2- Infected Young Individuals: Is It Type 1 Diabetes? Diabetes 2022;71:2656-2663Massimo Pietropaolo, Peter Hotez, Nick Giannoukakis
Clinical & Developmental Immunology|July 26, 2011
Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?Brett Phillips, Massimo Trucco, Nick Giannoukakis
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Genes and engineered cells as drugs for type I and type II diabetes mellitus therapy and preventionNick Giannoukakis, Massimo Pietropaolo, Massimo Trucco
Pageof 8

Showing results (21-30 of 76) with videos related to

Sort By:
Pageof 8
American Journal of Therapeutics|November 11, 2005
Gene therapy for type 1 diabetesNick Giannoukakis, Massimo Trucco
Clinical Immunology (Orlando, Fla.)|July 15, 2015
Nanotherapeutics for autoimmunity becomes mainstreamNick Giannoukakis, Wilson S Meng
Frontiers in Endocrinology|August 2, 2023
Editorial: Diabetes and non-alcoholic fatty liver disease: points of physiological and mechanistic intersection and current co-therapeutic approachesNick Giannoukakis, Kyle S McCommis
Expert Opinion on Drug Delivery|October 21, 2010
Drug delivery technologies for autoimmune diseaseBrett E Phillips, Nick Giannoukakis
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 10, 2002
Gene and cell therapies for diabetes mellitus: strategies and clinical potentialNick Giannoukakis, Paul D Robbins
Expert Review of Clinical Immunology|May 19, 2010
Dendritic cell-based therapy in Type 1 diabetes mellitusBrett Phillips, Nick Giannoukakis, Massimo Trucco
Pediatric Diabetes|June 11, 2008
Toward a cure for type 1 diabetes mellitus: diabetes-suppressive dendritic cells and beyondNick Giannoukakis, Brett Phillips, Massimo Trucco
Diabetes|November 21, 2022
Response to Comment on Pietropaolo et al. Incidence of an Insulin-Requiring Hyperglycemic Syndrome in SARS-CoV-2- Infected Young Individuals: Is It Type 1 Diabetes? Diabetes 2022;71:2656-2663Massimo Pietropaolo, Peter Hotez, Nick Giannoukakis
Clinical & Developmental Immunology|July 26, 2011
Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?Brett Phillips, Massimo Trucco, Nick Giannoukakis
Current Opinion in Investigational Drugs (London, England : 2000)|July 2, 2002
Genes and engineered cells as drugs for type I and type II diabetes mellitus therapy and preventionNick Giannoukakis, Massimo Pietropaolo, Massimo Trucco
Pageof 8